Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/ metastatic breast cancer[J]. Breast Cancer Res Treat, 2017, 166(1):167-177. [8] GIORDANO S H, ELIAS A D, GRADISHAR ...
其中,术后辅助治疗更新主要是基于2024年3月于《新英格兰杂志》正式刊登的NATALEE研究,本次登榜标志着瑞波西利在早期/局部晚期乳腺癌领域探索中再次突围,为更广泛的具有复发风险的HR+/HER2-乳腺癌开启了CDK4/6抑制剂辅助治疗新时代,...
7. Park, Yeon Hee, et al. "Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, ...
HR+/HER2-是乳腺癌中最常见的亚型,辅助内分泌治疗作为HR+/HER2-早期乳腺癌患者的标准治疗方案之一,显著改善了患者的治疗结局,但仍有部分患者经过标准治疗后复发、转移。目前针对患者的疾病复发风险分层选择合适的治疗方案已经成为临床上的普遍共识,内分泌治疗药物的不断更新升级也为患者提供了更多治疗选择。随着乳腺癌逐...
[6]Johnston S R D, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 20...
In this narrative review, we provide best-practice recommendations for the first-line treatment of HR /HER2– advanced breast cancer in Canada based on relevant literature, clinical guidelines, and our own clinical experience. Due to statistically significant improvements in...
10. Ahn S, et al. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation. J Pathol Transl Med. 2020;54(1):34-44. 11. Sajjadi E, et al. Improving HER2 testing reproducibility in HER2-low breast cancer. Cancer Drug Resist. 2022;5(4):882-888. ...
乳腺癌是一种在分子水平上具有高度异质性的肿瘤,包括多种组织学类型和分子亚型,因此显示出不同的表型和基因型差异,并且对治疗的反应以及预后也有很大不同1。激素受体阳性(HR+)乳腺癌是最常见的乳腺癌亚型,约…
值得一提的是,Capivasertib 是目前 HR+/HER2- 乳腺癌领域靶向联合内分泌治疗方案中全球最早「杀入」临床 III 期开发并达到主要终点的 AKT 通路抑制剂,同时也是全球首个拥有 Post-CDK4/6i 大型三期临床研究证据以及首个获批上市的 AKT 通路抑制剂,具有较高的临床应用前景,有望成为 HR+/HER2- 乳腺癌一线 CDK4...
报告最后,王磊苹教授进行了总结,她表示,HR+/HER2-乳腺癌新辅助治疗还未进入免疫治疗时代。但免疫治疗在早期HR+/HER2-乳腺癌治疗领域已经取得了治疗突破,预示着可能将会有一部分患者进入新辅助免疫治疗时代。 参考文献 上下滑动查看更多内容 1、Peter Schmid, et al.Neoadjuvant Pembrolizumab or Placebo Plus Chemotherap...